RecruitingObservational

Risk of Major Adverse Cardiovascular Events Among Users of Naldemedine Compared With Other Medications Used for Opioid Induced Constipation in Adult Patients With Chronic Non-Cancer Pain in a Healthcare Claims Database

NCT ID: NCT03720613Sponsor: BioDelivery Sciences InternationalLast updated: 2025-02-12

Summary

The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced constipation (OIC) medications.

Detailed description

This is a prevalent new user cohort study conducted using multiple databases linkable to medical records and the National Death Index (NDI) to assess MACE risk among adult patients with chronic non-cancer pain receiving naldemedine or a comparator OIC medication. The uptake of naldemedine and comparator OIC medications will be monitored for each database annually until a sufficient number of patients to support the comparative analyses in the safety assessment phase is accrued. The safety assessment phase will commence at the conclusion of the monitoring phase.

Arms & interventions

DrugNaldemedine
0.2 mg tablet once a day at any time with or without food
DrugLubiprostone
0.024 mg twice a day \[adjust dose based on liver function\]
DrugNaloxegol
25 mg tablet once a day in morning, 1 hour before or 2 hours after food

Outcome measures

Primary

Number of Participants with a Major Adverse Cardiovascular Event
A composite of major adverse cardiovascular events, cardiovascular (CV) death, nonfatal myocardial infarction (MI), and non-fatal stroke; participants with major adverse cardiovascular events will be identified using claims data and the national death index.
Time frame: 5 years

Secondary

Number of Participants with Cardiovascular Death
Time frame: 5 years
Number of Participants with Nonfatal Myocardial Infarction
Time frame: 5 years
Number of Participants with Nonfatal Stroke
Time frame: 5 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No

Inclusion Criteria: * At least one dispensing of naldemedine or lubiprostone or naloxegol without prior use in the database of either medication (index date) * At least two dispensings of opioids within six months prior to and including the index date, with at least a combined 31 cumulative days supply * At least 18 years of age or older on the index date * At least six months of continuous health plan coverage that includes medical and pharmacy benefits prior to and including the index date Exclusion Criteria: * Any acute MACE (non-fatal MI or non-fatal stroke) within six months before or on the index date * Any cancer treatment or cancer pain diagnosis within six months before or on the index date * Prior use of methylnaltrexone, alvimopan or naloxegol within six months before or on the index date

Study locations (1)

Research Site

Wilmington, Delaware, 19801

Recruiting